Bristol Myers Squibb reported positive Phase 3 head-to-head results showing izalontamab brengitecan (iza-bren) significantly prolonged progression-free survival versus platinum-based chemotherapy in patients with non-small cell lung cancer previously treated with an EGFR TKI. Median progression-free survival was 11.1 months with iza-bren versus 5.7 months in the chemotherapy arm, and the drug showed a manageable safety profile. The study was run in mainland China by Sichuan Biokin Pharmaceutical, parent of developer SystImmune, and the licensing deal includes an $800 million upfront payment and up to $7.1 billion in milestone payments. The author argues the muted stock reaction reflects China-only data, immature overall survival data, and competitors such as Johnson & Johnson developing similar drugs.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Bristol Myers Squibb’s Cancer Drug Just Doubled Survival Time Without Progression — Here’s Why It Matters
Read the original on Yahoo Finance ↗
Keywords
pharmaceuticalsBristol Myers Squibbhealthcare
Open a keyword to see other news on the same topic.
Related news
- Amgen vs . Bristol Myers Squibb : Which Healthcare Stock Is a Better Buy in 2026 ?
This comparison pits Amgen (AMGN) against Bristol Myers Squibb (BMY), with Amgen focused on biologics and BMY strong in oncology and hematology. In FY 2025, Amgen reported revenue of about $36.8 billion, up roughly 10%, net income of about $7.7 billion, a net margin near 21%, and free cash flow of nearly $8.1 billion. BMY generated revenue of about $48.2 billion, nearly flat, with net income of about $7.1 billion, a net margin near 14.6%, and free cash flow of about $12.8 billion. Amgen faces drug pricing pressure, an IRS tax dispute and biosimilar competition, while BMY relies heavily on Eliquis, which faces generic competition. The article describes BMY as cheaper, but says much of the difficulty appears priced in, so it is not an obvious buy right now.
- Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
Exelixis shares have risen 49% this year, but the FDA has extended the review of zanzalintinib, its investigational colorectal cancer drug, with a decision now expected by March 3, 2027, instead of December 3, 2026. The article argues the outlook remains attractive, citing three factors. First, Cabometyx, its main revenue driver, posted second-quarter revenue up 10.6% year over year to $628.7 million, and patent protection should keep generics out of the U.S. until at least 2030. Second, some analysts estimate zanzalintinib could generate $4.5 billion in U.S. sales by 2033, compared with $2.3 billion in revenue last year. Third, Exelixis has several other early-stage candidates and research collaborations in its pipeline.
- Bristol Myers Squibb vs. Eli Lilly: How Long Can Zepbound and Mounjaro Keep Juicing Revenue Results?
The article compares revenue growth at Bristol Myers Squibb and Eli Lilly. Lilly's growth is driven by GLP-1 drugs: Mounjaro brought in $9.9 billion worldwide in Q2 (up 91% year over year), Zepbound $4.9 billion in U.S. sales, and the oral Foundayo, launched in April 2026, $98 million in its first quarter. Bristol Myers Squibb (BMY) has steadier revenue, with no GLP-1 drug on the market and reliance on Eliquis and Opdivo, and its growth portfolio made up 58% of Q2 revenue. The article notes Bristol Myers Squibb trades at about 9.4 times forward earnings versus almost 25 times for Lilly, and says Lilly's two main products account for nearly two-thirds of quarterly sales, a concentration and pricing risk to its growth. Both companies report third-quarter results on Oct. 29.
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
J&J reported Phase 1 results for its investigational once-daily oral drug JNJ-6143: 12 of 16 patients with advanced prostate cancer and measurable tumors achieved a complete or partial response, or 75%, and its shares moved higher. Leerink called the results a potential 'game-changer', and J&J could share future development plans at its Dec. 8 Enterprise Business Review. The article also notes Meta's plan to raise up to $95 billion in equity, SpaceX's $40 billion debt raise to finance Nvidia GPU purchases, and Anthropic's IPO filing. Microsoft shares edged higher after it offered voluntary buyouts to about 60,000 eligible employees, which the author sees as a function of optimizing its operating structure rather than a sign of slowing business. Microsoft is expected to generate roughly $8 billion of free cash flow next quarter, versus outflows of $9.9 billion at Amazon and $2.3 billion at Alphabet, according to FactSet.
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady
Moderna shares fell 7% to $185.74 in morning trading after its personalized melanoma vaccine, intismeran autogene, given with Keytruda, met its primary goal of reducing the risk of recurrence or death, but its effect on distant metastasis was far smaller than an earlier mid-stage study suggested. Detailed late-stage results were released on October 22 ahead of a conference in Madrid. BioNTech fell 3% to $85.65, Merck fell 0.2% to $145.61 and Pfizer fell 0.2% to $29.96, while the iShares Biotechnology ETF rose 0.2% to $208.21. The article notes Moderna's business relies entirely on mRNA medicines, so the vaccine carries a large share of its pipeline value, and says the next step is whether the full dataset supports a regulatory filing.
Related markets
Latest news
- Solana bug reports now cost 1 SOL as AI floods security teams with spam
Firedancer, the Solana software developed by Jump Crypto, now requires researchers to permanently burn 1 SOL (about $100) for each bug report; the cost is nonrefundable even if a report is invalid or duplicates an earlier finding, and reports submitted without a burn are ineligible for rewards. The change follows a monthlong $1 million audit competition that drew 809 reports from 162 researchers but produced only 127 unique security findings, with nearly half of valid submissions duplicating earlier reports. Jump believes AI helped discover or write nearly every submission, which slowed engineers' validation work. To offset this, Jump is temporarily doubling payouts, and tripling them for Alpenglow, Solana's new voting system, where critical findings can qualify for up to $300,000.
- VinaCapital investor group cuts Kido stake below 6%
VinaCapital's fund management company reported that Liva Holdings Limited sold 1.9 million KDC shares in the October 22, 2026 session, cutting its stake from 5.16% to 4.47% of Kido's charter capital. Including Vina QSR Limited, which holds over 2.6 million shares (0.95%), the group's combined stake fell from 6.11% to 5.42%. Separately, Kido completed two share transfers in Thực phẩm Đông lạnh Kido (now Nuti KD) and, as of September 18, 2026, held only 14.7% of its charter capital, so Nuti KD is no longer an associate of KDC. Shareholders also approved canceling contracts that transferred 34 trademarks, including Merino and Celano, and Kido will complete procedures to restore ownership of these trademarks to Thực phẩm Đông lạnh Kido.
- Bitcoin ETFs claw back $110M after $774M exit
US spot Bitcoin ETFs returned to net inflows of $110 million on Monday, after $774 million in outflows over the previous two trading sessions, according to SoSoValue. October remained negative, with about $202 million in net outflows through Monday. Bitcoin traded at $79,595 at publication, down 2.6% over the past seven days per CoinGecko, while the Crypto Fear & Greed Index fell to 48 from 50, staying in 'Neutral' territory. CryptoQuant data showed retail deposits to Binance nearly doubled over 30 days to $10.8 billion, while deposits from large holders fell to $3.8 billion, and analyst Darkfost suggested smaller investors may be using the price rebound to sell.
- Opinion: UK bond investors want spending cuts. John Healey's first Budget may disappoint
An opinion piece says Chancellor John Healey has handled preparation of his first budget with far less rumor than predecessor Rachel Reeves, but major challenges remain. Fiscal headroom has shrunk from £24 billion ($32 billion) to as little as £10 billion because of higher government borrowing costs, while Prime Minister Andy Burnham has made several spending commitments, the latest a £432-million plan to tackle homelessness. Healey must explain how to fund tax cuts, including extended fuel duty relief that could cost over £2 billion, and how to lift defense spending to 3% of GDP by the end of the decade, while tax increases targeting banks and gambling firms remain likely. The Financial Times reported that the National Wealth Fund and British Business Bank will be handed £20.4 billion, a move that exploits a loophole in fiscal rules. National debt has just risen above £3 trillion, and harder decisions on youth unemployment and welfare spending will not be published until later this year.
- Global oil and gas industry expected to spend $7.5 billion on AI, how is FPT taking part?
FPT is applying AI to core oilfield operations, starting with cement plugging of wells, where a services group that had to run up to 17,000 experiments a month now uses an FPT-built model trained on about 9 million cleaned records. The model raised prediction accuracy from about 60% to 79%, averages 1.6 seconds per prediction, and screens out low-probability formulas to reduce physical testing. In safety, FPT and an Asian oil and gas client deployed Vision AI to flag rule violations from site cameras; the company estimates it avoided 15 potentially fatal incidents and 110 injury incidents, about $2.54 million in losses. According to The Business Research Company, the global AI market in oil and gas is expected to reach $4.55 billion in 2026 and $7.51 billion by 2030.
- HOSE updates list of stocks ineligible for margin trading at end of October
HOSE updated its list of 67 stocks and fund certificates ineligible for margin trading as of October 26, 2026, adding DSH of Đông Sơn Holdings because it has been listed for less than six months. DSH listed 35 million shares on HOSE on October 26, with total listed value of 350 billion VND at par, a reference price of 11,900 VND per share in its first session, and a ±20% price band. Other codes remain on the list due to warning or control status, trading restrictions, negative after-tax profit attributable to parent shareholders in the 2026 half-year reviewed statements, or half-year review reports lacking an unqualified opinion.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.